A detailed history of Royal Bank Of Canada transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 18,468 shares of HRTX stock, worth $29,179. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,468
Previous 17,208 7.32%
Holding current value
$29,179
Previous $60,000 40.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.73 - $3.67 $2,179 - $4,624
1,260 Added 7.32%
18,468 $36,000
Q2 2024

Aug 14, 2024

BUY
$2.32 - $3.86 $11,999 - $19,963
5,172 Added 42.97%
17,208 $60,000
Q1 2024

Nov 05, 2024

SELL
$1.71 - $3.06 $8,844 - $15,826
-5,172 Reduced 30.06%
12,036 $33,000
Q1 2024

May 15, 2024

SELL
$1.71 - $3.06 $52,722 - $94,345
-30,832 Reduced 71.92%
12,036 $33,000
Q4 2023

Feb 14, 2024

BUY
$0.54 - $1.82 $14,929 - $50,317
27,647 Added 181.64%
42,868 $72,000
Q3 2023

Nov 14, 2023

BUY
$0.97 - $1.8 $5,845 - $10,846
6,026 Added 65.54%
15,221 $15,000
Q2 2023

Aug 14, 2023

SELL
$1.11 - $2.88 $2,614 - $6,782
-2,355 Reduced 20.39%
9,195 $10,000
Q1 2023

May 15, 2023

SELL
$1.51 - $3.25 $8,335 - $17,940
-5,520 Reduced 32.34%
11,550 $17,000
Q4 2022

Feb 14, 2023

BUY
$2.25 - $4.67 $24,734 - $51,337
10,993 Added 180.9%
17,070 $42,000
Q3 2022

Nov 14, 2022

SELL
$2.66 - $5.37 $6,668 - $13,462
-2,507 Reduced 29.21%
6,077 $25,000
Q2 2022

Aug 15, 2022

SELL
$2.3 - $6.29 $51,161 - $139,914
-22,244 Reduced 72.16%
8,584 $25,000
Q1 2022

May 16, 2022

SELL
$4.63 - $9.94 $47,911 - $102,859
-10,348 Reduced 25.13%
30,828 $176,000
Q4 2021

Feb 14, 2022

BUY
$8.35 - $12.6 $117,392 - $177,143
14,059 Added 51.85%
41,176 $376,000
Q3 2021

Nov 15, 2021

BUY
$10.13 - $15.0 $44,268 - $65,550
4,370 Added 19.21%
27,117 $290,000
Q2 2021

Aug 16, 2021

BUY
$13.27 - $18.48 $301,852 - $420,364
22,747 New
22,747 $353,000

Others Institutions Holding HRTX

About HERON THERAPEUTICS, INC.


  • Ticker HRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,774,000
  • Market Cap $188M
  • Description
  • Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...
More about HRTX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.